Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

G. Bacci, P. Picci, S. Ferrari, P. Ruggieri, R. Casadei, A. Tienghi, A. B. Del Prever, F. Gherlinzoni, M. Mercuri, C. Monti

Research output: Contribution to journalArticle

Abstract

Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (

Original languageEnglish
Pages (from-to)3227-3238
Number of pages12
JournalCancer
Volume72
Issue number11
DOIs
Publication statusPublished - 1993

Fingerprint

Osteosarcoma
Methotrexate
Doxorubicin
Cisplatin
Extremities
Drug Therapy
Disease-Free Survival
Necrosis
Italy
Survival Rate
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • limb salvage
  • malignant bone tumors
  • neoadjuvant chemotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities : Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. / Bacci, G.; Picci, P.; Ferrari, S.; Ruggieri, P.; Casadei, R.; Tienghi, A.; Del Prever, A. B.; Gherlinzoni, F.; Mercuri, M.; Monti, C.

In: Cancer, Vol. 72, No. 11, 1993, p. 3227-3238.

Research output: Contribution to journalArticle

Bacci, G. ; Picci, P. ; Ferrari, S. ; Ruggieri, P. ; Casadei, R. ; Tienghi, A. ; Del Prever, A. B. ; Gherlinzoni, F. ; Mercuri, M. ; Monti, C. / Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities : Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. In: Cancer. 1993 ; Vol. 72, No. 11. pp. 3227-3238.
@article{1ee306f8e7284d5684bbadc445d36a2a,
title = "Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin",
abstract = "Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90{\%} tumor necrosis) received three more cycles of these drugs, whereas poor responders (",
keywords = "limb salvage, malignant bone tumors, neoadjuvant chemotherapy, osteosarcoma",
author = "G. Bacci and P. Picci and S. Ferrari and P. Ruggieri and R. Casadei and A. Tienghi and {Del Prever}, {A. B.} and F. Gherlinzoni and M. Mercuri and C. Monti",
year = "1993",
doi = "10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C",
language = "English",
volume = "72",
pages = "3227--3238",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities

T2 - Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

AU - Bacci, G.

AU - Picci, P.

AU - Ferrari, S.

AU - Ruggieri, P.

AU - Casadei, R.

AU - Tienghi, A.

AU - Del Prever, A. B.

AU - Gherlinzoni, F.

AU - Mercuri, M.

AU - Monti, C.

PY - 1993

Y1 - 1993

N2 - Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (

AB - Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and in disease-free survival. Patients with a good response to preoperative chemotherapy showed a higher disease-free survival rate. Current studies examine the possibility of patients whose limbs could be rescued with a poor necrosis and a reduction of the side effects related to aggressive treatments. Methods. Between September 1986 and December 1989, 164 patients entered the second neoadjuvant study conducted at the Rizzoli Institute, Bologna, Italy, for nonmetastatic osteosarcoma of the extremities. Preoperative chemotherapy consisted of two cycles of high-dose methotrexate intravenously (IV) followed by cisplatin intraarterially and doxorubicin IV. After surgery, patients classified as good responders (> 90% tumor necrosis) received three more cycles of these drugs, whereas poor responders (

KW - limb salvage

KW - malignant bone tumors

KW - neoadjuvant chemotherapy

KW - osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0027381042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027381042&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C

DO - 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C

M3 - Article

C2 - 8242546

AN - SCOPUS:0027381042

VL - 72

SP - 3227

EP - 3238

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -